• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/6/25 4:35:09 PM ET
    $BIOA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BIOA alert in real time by email
    8-K
    0001709941false00017099412025-05-062025-05-06

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 06, 2025

     

     

    BIOAGE LABS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-42279

    47-4721157

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    5885 Hollis Street

    Suite 370

     

    Emeryville, California

     

    94608

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: 510 806-1445

     

    1445A South 50th Street Richmond, CA 94804

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, $0.00001 Par Value Per Share

     

    BIOA

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 6, 2025, BioAge Labs, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

    The information in this Item 2.02, including Exhibit 99.1 attached to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in the accompanying Exhibit 99.1 shall not be incorporated by reference into any other filing under the Exchange Act or under the Securities Act, except as shall be expressly set forth by specific reference in such filing.

    Item 9.01 Financial Statements and Exhibits.


    (d) Exhibits

     

     

     

     

    Exhibit
    No.

     Description

    99.1

    Press release issued by BioAge Labs, Inc. dated May 6, 2025.

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document).


     


     

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    BIOAGE LABS, INC.

     

     

     

     

    Date:

    May 6, 2025

    By:

    /s/ Dov Goldstein

     

     

     

    Dov Goldstein, M.D.
    Chief Financial Officer

     


    Get the next $BIOA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BIOA

    DatePrice TargetRatingAnalyst
    2/28/2025Mkt Perform
    William Blair
    12/10/2024$40.00 → $5.00Overweight → Underweight
    Morgan Stanley
    12/9/2024$42.00 → $7.00Buy → Hold
    Jefferies
    12/9/2024$45.00 → $7.00Buy → Neutral
    Citigroup
    10/21/2024$45.00Buy
    Citigroup
    10/21/2024$42.00Buy
    Jefferies
    10/21/2024$40.00Overweight
    Morgan Stanley
    More analyst ratings

    $BIOA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by BioAge Labs Inc.

      SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

      11/14/24 4:15:56 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by BioAge Labs Inc.

      SC 13G - BioAge Labs, Inc. (0001709941) (Subject)

      11/12/24 4:15:53 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by BioAge Labs Inc.

      SC 13D - BioAge Labs, Inc. (0001709941) (Subject)

      10/4/24 8:21:35 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:11:28 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:10:37 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Pande Vijay Satyanand bought $4,329,019 worth of shares (219,195 units at $19.75) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      10/3/24 7:19:49 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • BioAge Labs Reports First Quarter 2025 Financial Results and Provides Business Updates

      Advancement of lead candidate BGE-102, an oral, brain-penetrant NLRP3 inhibitor for obesity, with initial clinical data expected 2H25New strategic collaboration with Lilly ExploR&D expands therapeutic approach to novel metabolic aging targetsProgression of preclinical next-generation APJ agonists for obesity RICHMOND, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided business updates and reported its first quarter 2025 financial results. "The first quarter of 2025 was marke

      5/6/25 4:30:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs Reports Full Year 2024 Financial Results and Provides Business Updates from the Fourth Quarter of 2024

      Advancement of oral, brain-penetrant NLRP3 inhibitor BGE-102, with initial clinical data expected 2H25 Progression of preclinical next-generation APJ agonists for obesity New platform partnerships with Novartis and Lilly to discover and develop novel therapies for conditions driven by metabolic aging RICHMOND, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended Decembe

      3/20/25 4:30:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioArctic receives Orphan Drug Designation for exidavnemab the US

      STOCKHOLM, March 17, 2025 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the US FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation (ODD) to exidavnemab for the treatment of Multiple System Atrophy (MSA), providing incentives for the development of treatments for rare diseases with a high medical need. Multiple System Atrophy (MSA) is a rapidly progressive and fatal rare disease affecting the central and autonomic nervous systems. MSA is characterized by pathological alpha-synuclein aggregation, that causes gradual damage to nerve cells in the brain. This affects balance, movement and the autonomic nervous system, which

      3/17/25 1:49:00 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • William Blair initiated coverage on BioAge Labs

      William Blair initiated coverage of BioAge Labs with a rating of Mkt Perform

      2/28/25 7:20:24 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded BioAge Labs from Overweight to Underweight and set a new price target of $5.00 from $40.00 previously

      12/10/24 7:54:08 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs downgraded by Jefferies with a new price target

      Jefferies downgraded BioAge Labs from Buy to Hold and set a new price target of $7.00 from $42.00 previously

      12/9/24 7:29:20 AM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    SEC Filings

    See more
    • SEC Form 10-Q filed by BioAge Labs Inc.

      10-Q - BioAge Labs, Inc. (0001709941) (Filer)

      5/6/25 4:40:22 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - BioAge Labs, Inc. (0001709941) (Filer)

      5/6/25 4:35:09 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by BioAge Labs Inc.

      DEFA14A - BioAge Labs, Inc. (0001709941) (Filer)

      4/17/25 4:10:03 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BIOA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Director Hemrajani Rekha bought $54,000 worth of shares (3,000 units at $18.00) (SEC Form 4)

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:11:28 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Principal Accounting Officer Barton Shane bought $47,376 worth of shares (2,632 units at $18.00) (SEC Form 4)

      4 - BioAge Labs, Inc. (0001709941) (Issuer)

      3/10/25 4:10:37 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 4 filed by Chief Operating Officer Morgen Eric

      4/A - BioAge Labs, Inc. (0001709941) (Issuer)

      2/25/25 4:28:11 PM ET
      $BIOA
      Biotechnology: Pharmaceutical Preparations
      Health Care